GlassScriptPhysician profile
Barton R Paschal
NPI 1063452506
$2,267.63
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,249 · 2020: $18.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $251.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $231.90 | 2019 | |
| Genentech USA, INC. | $215.41 | 2019 | |
| Pfizer INC. | $180.90 | 2019 | |
| Amgen INC. | $152.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.55 | 2019 | |
| Eisai INC. | $125.53 | 2019 | |
| Celgene Corporation | $111.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $90.93 | 2019 | |
| Astellas Pharma US INC | $63.20 | 2019 | |
| Exelixis INC. | $62.52 | 2019 | |
| Rigel Pharmaceuticals, INC. | $57.34 | 2019 | |
| Merck Sharp & Dohme LLC | $55.28 | 2019 | |
| Genzyme Corporation | $53.29 | 2019 | |
| Incyte Corporation | $52.61 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.57 | 2019 | |
| Taiho Oncology, INC. | $44.47 | 2019 | |
| Janssen Biotech, INC. | $43.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $42.97 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $42.65 | 2019 | |
| Seagen INC. | $39.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.49 | 2019 | |
| Emd Serono, INC. | $25.59 | 2019 | |
| Puma Biotechnology, INC. | $23.39 | 2019 | |
| Abbvie INC. | $18.66 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.24 | 2019 | |
| Fortovia Therapeutics, INC. | $14.15 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.31 | 2019 | |
| Kyowa Kirin, INC. | $13.09 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barton Paschal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.